Get the Stockscreener App
27.43
5.64%
-1.64
After Hours:
27.81
0.38
+1.39%
Avalyn Pharma Inc stock is traded at $27.43, with a volume of 467.95K.
It is down -5.64% in the last 24 hours and up +0.00% over the past month.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
See More
Previous Close:
$29.07
Open:
$29.32
24h Volume:
467.95K
Relative Volume:
37.44
Market Cap:
$1.15B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$25.44
$29.64
1-Week Range:
$25.44
$30.67
52-Week Range:
$25.44
$30.67
Avalyn Pharma Inc Stock (AVLN) Company Profile
Compare AVLN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVLN
Avalyn Pharma Inc
|
27.43 | 1.22B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Avalyn Pharma Inc Stock (AVLN) Latest News
Avalyn brings patient feedback on lung fibrosis care to ATS 2026 - Stock Titan
Avalyn to Present Patient-Centered Research on AP01 - GlobeNewswire
Lung disease drug developer Avalyn surges on public debut - MSN
Preferred dividends of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Cash per share of Avalyn Pharma Inc. – BOATS:AVLN - TradingView
Avalyn Pharma (AVLN) Stock Trends and Sentiment 2026 - MarketBeat
Avalyn Pharma (AVLN) 10K Form and Latest SEC Filings 2026 - MarketBeat
Finance Watch: Avalyn, Hemab And Seaport Launch $856m Worth Of IPOs - Citeline News & Insights
Avalyn Pharma completes $345 million IPO on nasdaq - Investing.com
Avalyn Pharma completes $345 million IPO on nasdaq By Investing.com - Investing.com Canada
Avalyn Pharma closes $345 million IPO on Nasdaq - Investing.com
Avalyn raises $345M as underwriters take all extra IPO shares - Stock Titan
Avalyn Pharma Inc. (AVLN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Avalyn Announces Closing of Initial Public Offering and - GlobeNewswire
Avalyn Pharma Inc. (AVLN) Stock Price Today & Analysis - Gotrade
AVLN Price Today: Avalyn Pharma Inc. Stock Price, Quote & Chart | MEXC - MEXC
Avalyn Pharma (AVLN): Upsized and Oversubscribed, Avalyn Pharma Delivers Breakout IPO - Smartkarma
EDGAR Filing Documents for 0001193125-26-197686 - SEC.gov
Avalyn Pharma Inc.(NasdaqGS: AVLN) added to NASDAQ Composite Index - marketscreener.com
Avalyn Pharma raises $300M in IPO, shares surge 64% on first day of trading - The Business Journals
Goodwin, Davis Polk Lead Avalyn's Upsized $300M IPO - Law360
Novo-Backed Drugmaker Avalyn Soars 44% After $300 Million US IPO - Bloomberg.com
Is Avalyn Pharma (NASDAQ:AVLN) In A Good Position To Invest In Growth? - Yahoo Finance
Pulmonary drug developer Avalyn surges on IPO (AVLN:NASDAQ) - Seeking Alpha
Avalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials - MedCity News
Mists of Avalyn thicken with $300M IPO for inhaled drugs - BioWorld News
Avalyn Pharma prices $300M IPO at $18 per share - MSN
Avalyn Pharma IPO ends oversubscribed with concentrated allocations - Investing.com
Avalyn Pharma Rings the Opening Bell - Nasdaq
Avalyn Pharma Inc (AVLN) Stock Price, News & Analyst Forecast - eToro
Avalyn Sets IPO Price At $18 Per Share - RTTNews
IPO Tracker 2026: Avalyn beats expectations with $300M debut - BioSpace
Avalyn prices upsized IPO at $18 per share, raising $300 million - Investing.com
Avalyn Pharma prices upsized IPO at $18 per share for $300 million - Investing.com
Avalyn Pharma raises $300M in IPO - Axios
Novo-Backed Drugmaker Avalyn Raises $300 Million in Upsized IPO - Bloomberg.com
Avalyn Pharma prices upsized IPO at $18 per share - Investing.com
Avalyn, in pursuit of better lung drugs, banks $300M in an IPO - BioPharma Dive
Avalyn Announces Pricing of Upsized Initial Public Offering - The Manila Times
AVLN : Avalyn Pharma Key Company Details - Zacks Investment Research
AVLN : AVALYN PHARMA Key Company Metrics & Non-finance Metrics - Zacks Investment Research
EDGAR Filing Documents for 0001193125-26-189477 - SEC.gov
Avalyn Pharma Inc. Income Statement – NASDAQ:AVLN - TradingView
Avalyn Pharma Inc. Dividends – NASDAQ:AVLN - TradingView
Net income before discontinued operations of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
AVALYN PHARMA INC Balance Sheet – NASDAQ:AVLN - TradingView
Total debt of Avalyn Pharma Inc. – NASDAQ:AVLN - TradingView
Free cash flow of AVALYN PHARMA INC – NASDAQ:AVLN - TradingView
AVALYN PHARMA INC Earnings and Revenue – NASDAQ:AVLN - TradingView
Avalyn Strengthens Leadership Team to Support Long-Term Growth with Appointments of Industry Leaders Adam Golden and Frank Salisbury - Yahoo Finance
Basic earnings per share (basic EPS) of AVALYN PHARMA INC – NASDAQ:AVLN - TradingView
Avalyn Pharma Inc Stock (AVLN) Financials Data
There is no financial data for Avalyn Pharma Inc (AVLN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):